New York-based Paradigm has raised a significant amount to simplify clinical trials. Its goal is ambitious, but its challenges are many, researchers say.
Previous Story
U.S. Economy Grew at 2.9% Annual Rate in Fourth Quarter
Next Story
Your Investment Lost Money Last Year. So Why the Big Tax Bill?
